Career Development Series

Exploring Academic Landscape—Entrepreneurial Spirit in ​Taiwan



BTBA is thrilled to invite two distinguished individuals who wear the hats of both professors and CEOs, each having founded their own companies. They will be sharing their wealth of experiences, delving into the motivations behind their entrepreneurial journeys, the challenges faced, the rewards reaped, and the personal evolution entailed in operating a company. Whether you’re intrigued by the transformation of academic research into entrepreneurial resources in Taiwan or contemplating a return to Taiwan for entrepreneurial pursuits in the future, please join us at this event, which will be held in Mandarin Chinese.

▶️ 主題 / Topic: Exploring Academic Landscape: Entrepreneurial Spirit in ​Taiwan

▶️ 時間 / Time:

  • Boston: 9:00 pm to 10:30 pm (EST), Jan 26, 2024 (Friday)
  • Taiwan: 10:00 am to 11:30 am (GMT+8), Jan 27, 2024 (Saturday)

▶️ 活動地點/Venue: Online event,會議連結將在此問卷結束後提供並在會議幾天前寄出email提醒。

▶️ 報名連結/RSVP :

▶️ 講者 Speakers:

  • Kuo-Hsiang Chuang Ph.D. (莊國祥)
    • Professor at Graduate Institute of Pharmacognosy, Taipei Medical University
    • CEO & Founder of CytoArm Co. Ltd (賽昂生醫)
    • 👏 2023環球生技台灣CEO首獎 👏
  • Cheng-Chih Hsu Ph.D. (徐丞志)
    • Professor at Department of Chemistry, National Taiwan University
    • CEO & Founder of Leeuwenhoek Laboratories Co. Ltd (雷文虎克生技)
    • 👏 網路票選十大2023 Best Bio Startup CEOs 👏

▶️ 活動負責人 Organizers:

  • Yi-En Liao Ph.D. (廖怡恩)
    • Novartis Clinical Science and Innovation fellow
  • Wei-Chao Huang, Ph.D. (黃威超)
    • Postdoctoral associate at the Broad Institute of MIT and Harvard


Kuo-Hsiang Chuang Ph.D. (莊國祥)

Dr. Chuang is a professor at Taipei Medical University (台北醫學大學) and the CEO/founder of CytoArm Co., Ltd (賽昂生醫). Dr. Chuang completed his Ph.D. at Kaohsiung Medical University in 2010 with more than 20-year experience in multifunctional antibody drugs, novel tumor-specific T-cell technology platforms, novel protein drugs for the treatment of autoimmune diseases, and a variety of tandem repeated protein technologies that can be applied to enhance the sensitivity of immunoassay technology.

Cheng-Chih Hsu Ph.D. (徐丞志)

Dr. Hsu is an associate professor in the Chemistry department at National Taiwan University (台灣大學) and the founder/CEO of Leeuwenhoek Laboratories Co. Ltd (雷文虎克生技). He received his Ph.D. at the University of California San Diego and was trained as a postdoctoral fellow at Stanford University. His research is focused on using mass spectrometry to explore the chemistry of complex biological systems and clinical applications, especially human microbiota. He was selected as one of the “Top 40 Under 40” by the Analytical Scientist in 2018 and rewarded with the MOST Young Scholar Fellowship – Columbus Program (哥倫布計畫) in 2019.


Yi-En Liao Ph.D. (廖怡恩)

Yi-En is a Novartis clinical science and innovation fellow in Boston, working on early-phase clinical trial development and operation. She moved to the U.S. for an M.S. and a Ph.D. in Pharmaceutical Science at the University of Southern California and the University of North Carolina at Chapel Hill, respectively, after her pharmacist training at Taipei Medical University in Taiwan. During Yi-En’s academic training, her research focused on the development of anti-inflammatory treatments for inflammatory diseases, including traumatic brain injury, sepsis, and acute liver injury.

Wei-Chao Huang, Ph.D. (黃威超)

Wei-Chao is currently working as a postdoctoral associate at the Broad Institute of MIT and Harvard. He holds an M.S. in Neuroscience from NYMU in Taiwan and a Ph.D. in Neurobiology from the University of Utah. During his Ph.D. studies, Wei-Chao worked on many projects that used next-generation sequencing to determine the epigenetic mechanisms and allele-specific expression effects. Furthermore, he and lab members built a startup team with the Lassonde Entrepreneur Institute to put the research findings into practice. In 2019, he relocated to Boston to work at Amgen. Presently, he is studying the mechanisms of neuropsychiatric disorders through mouse models at the Broad Institute.

2024-01-26, 9:00–10:30 PM ET

Register here